Goodwill and Other Intangible Assets (Product Rights and License by Therapeutic Category) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net	$ 22,566.9	$ 26,087.7
Product rights and licenses
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net	22,565.9	26,084.5
Product rights and licenses | Developed Markets
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net	12,211.1	14,313.6
Product rights and licenses | Greater China
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net	5,642.9	6,115.0
Product rights and licenses | JANZ
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net	1,325.5	1,495.8
Product rights and licenses | Emerging Markets
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net	3,386.4	4,160.1
Product rights and licenses | Brands
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net	18,578.3	21,146.0
Product rights and licenses | Brands | Developed Markets
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net	8,762.2	10,066.6
Product rights and licenses | Brands | Greater China
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net	5,632.3	6,102.9
Product rights and licenses | Brands | JANZ
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net	1,061.3	1,174.8
Product rights and licenses | Brands | Emerging Markets
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net	3,122.5	3,801.7
Product rights and licenses | Complex Gx and Biosimilars
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net	178.4	228.3
Product rights and licenses | Complex Gx and Biosimilars | Developed Markets
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net	177.5	226.8
Product rights and licenses | Complex Gx and Biosimilars | Greater China
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net	0.0	0.0
Product rights and licenses | Complex Gx and Biosimilars | JANZ
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net	0.9	1.5
Product rights and licenses | Complex Gx and Biosimilars | Emerging Markets
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net	0.0	0.0
Product rights and licenses | Generics
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net	3,809.2	4,710.2
Product rights and licenses | Generics | Developed Markets
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net	3,271.4	4,020.2
Product rights and licenses | Generics | Greater China
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net	10.6	12.1
Product rights and licenses | Generics | JANZ
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net	263.3	319.5
Product rights and licenses | Generics | Emerging Markets
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net	$ 263.9	$ 358.4